Rossi G P, Pessina A C, Semplicini A, Feltrin G P, Mozzato M G, Dissegna L, Dal Palu' C
Jpn Heart J. 1986 May;27(3):299-305. doi: 10.1536/ihj.27.299.
Recurrence of hypertension is reported in a considerable percentage of renovascular hypertensive patients treated by percutaneous transluminal angioplasty (PTRA); among the possible mechanisms for these failures, restenosis of the renal artery is the only correctable one. Since captopril stimulates renin secretion to a greater extent in renovascular than in essential hypertensive patients, we determined if it could be used to unmask significant restenosis in the patients with hypertension recurring after PTRA. Follow-up study was performed in 28 patients treated with PTRA. We found that captopril caused a greater increase in peripheral plasma renin activity in 8 of 8 cases who had recurrence of hypertension and restenosis than in 13 of 15 of the patients who did not. We suggest that the determination of captopril-stimulated renin may provide a useful, simple and economical tool for the detection of restenosis after PTRA.
据报道，在接受经皮腔内血管成形术（PTRA）治疗的肾血管性高血压患者中，相当一部分会出现高血压复发；在这些治疗失败的可能机制中，肾动脉再狭窄是唯一可纠正的机制。由于卡托普利在肾血管性高血压患者中比在原发性高血压患者中更能刺激肾素分泌，我们研究了它是否可用于揭示PTRA后高血压复发患者的显著再狭窄情况。对28例接受PTRA治疗的患者进行了随访研究。我们发现，在8例高血压复发且有再狭窄的患者中，有8例卡托普利引起的外周血浆肾素活性升高幅度大于15例未复发患者中的13例。我们认为，测定卡托普利刺激后的肾素水平可能为检测PTRA后的再狭窄提供一种有用、简单且经济的方法。
